Skip to content

Search

2021 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful recipients for the 2021 Round 2 Seed Funding Grants. Julie Hibbert | Validating a

2017 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2017 Round 2 Wesfarmers Centre Seed Funding. The Wesfarmers Centre

2017 Round 1 Seed Funding Recipients

Congratulations goes to Dr Asha Bowen and Dr Ruth Thornton for being the successful first round recipients of the WCVID.

2016 Round 2 Seed Funding Recipients

The Wesfarmers Centre is pleased to announce the successful applications for the 2016 Round 2 Wesfarmers Centre Seed Funding.

2015 Seed Funding Recipients

Eight applicants were successful, and were awarded $15,000 each for activities supporting subsequent research grant applications.

2014 Seed Funding Recipients

In 2014, the Wesfarmers Centre of Vaccines & Infectious Diseases put out a first call for seed funding proposals.

Spritz-OM

Preventing over half of the world’s ear infections with a therapy such as Spritz-OM will significantly improve health and educational outcomes on a global scale.

Wesfarmers Centre of Vaccines and Infectious Diseases Deborah Lehmann Research Award

The Wesfarmers Centre has established the Deborah Lehmann Research Award to acknowledge the significant contribution that Clinical Associate Professor Deborah Lehmann AO has made to paediatric infectious disease research.

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.

Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.